Provided by Tiger Trade Technology Pte. Ltd.

Filana Therapeutics

0.9300
-0.0310-3.23%
Post-market: 0.93600.0060+0.65%19:30 EDT
Volume:121.94K
Turnover:114.43K
Market Cap:44.93M
PE:-1.06
High:0.9507
Open:0.9499
Low:0.9201
Close:0.9610
52wk High:4.98
52wk Low:0.8513
Shares:48.31M
Float Shares:47.32M
Volume Ratio:0.42
T/O Rate:0.26%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8752
EPS(LYR):-1.8836
ROE:-55.78%
ROA:-7.14%
PB:0.71
PE(LYR):-0.49

Loading ...

Company Profile

Company Name:
Filana Therapeutics
Exchange:
NASDAQ
Establishment Date:
1998
Employees:
19
Office Location:
6801 N. Capital of Texas Highway,Building 1,Austin,Texas,United States
Zip Code:
78731
Fax:
- -
Introduction:
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.

Directors

Name
Position
Claude Nicaise
Chairman of the Board and Director
Richard J. Barry
Chief Executive Officer and Director and President
Dawn Carter Bir
Director
Michael J. O'donnell
Director
Patrick J. Scannon
Director
Pierre Gravier
Director
Robert Anderson
Director
Robert Z. Gussin
Director

Shareholders

Name
Position
Richard J. Barry
Chief Executive Officer and Director and President
Eric J. Schoen
Chief Financial Officer
R. Christopher Cook
Chief Operating and Legal Officer